The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2009Enzymes that Catalyze for Alpha-synuclein Ubiquitination and Degradation
Objective/Rationale:
A characteristic feature of Parkinson’s disease (PD) is the buildup of the protein, alpha-synuclein, and overproduction of this protein can trigger PD. Therefore, it is important... -
Rapid Response Innovation Awards, 2009Small Molecule Inhibitors of Alpha-synuclein Assembly and Toxicity
Objective/Rationale:
We will test a novel drug candidate that blocks formation of the toxic aggregates of the protein alpha-synuclein, which are believed to cause Parkinson’s disease (PD). Our drug... -
Target Validation, 2009Upregulation of MsrA: A Neuroprotective Strategy for the Treatment of Parkinson's Disease
Objective/Rationale:
The death of neurons in the brains of Parkinson’s disease (PD) patients involves a buildup of agents that cause oxidative stress, resulting in damage to proteins, lipids, and DNA... -
Therapeutics Development Initiative, 2009Exploring Curcumin and Curcumin Derivatives as Putative Epigenetic Target of Histone Deacetylase (HDAC) Inhibition in Parkinson's Disease
Objective/Rationale:
Our project is to explore cutting-edge nano- biotechnology advances in formulating curcumin extracted from Curry as potential drug candidates in treatment of Parkinson disease... -
Therapeutics Development Initiative, 2009Assessment of the Therapeutic Efficacy of Progranulin in a Sub-chronic Small Model of Parkinson's Disease
Objective/Rationale:
Progranulin (PGRN), a protein found in the brain, is thought to promote the survival and health of brain cells. Neurodyn Inc. has discovered PGRN to have disease-modifying effects... -
Therapeutics Development Initiative, 2009Optimising Lead Series of Small Molecule Inhibitors of LRRK2 to Deliver Tool Compounds and Clinical Development Candidates
Objective/Rationale:
The exciting discovery of activating mutations in the LRRK2 kinase in a subset of familial PD patients provides a route to better understanding of signaling pathways that, when...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.